Provided By GlobeNewswire
Last update: Oct 12, 2024
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-
NASDAQ:BNTC (7/29/2025, 2:50:54 PM)
11.16
+0.14 (+1.27%)
Find more stocks in the Stock Screener